Axonics Full Year 2023 Earnings: EPS Beats Expectations
Axonics (NASDAQ:AXNX) Full Year 2023 Results
Key Financial Results
Revenue: US$366.4m (up 34% from FY 2022).
Net loss: US$6.09m (loss narrowed by 90% from FY 2022).
US$0.12 loss per share (improved from US$1.28 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Axonics EPS Beats Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 41%.
Looking ahead, revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US.
Performance of the American Medical Equipment industry.
The company's share price is broadly unchanged from a week ago.
Balance Sheet Analysis
Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We have a graphic representation of Axonics' balance sheet and an in-depth analysis of the company's financial position.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
